Research Library
ACE-083 research
6 articles to explore, with links to 5 original sources.
About ACE-083
ACE-083 is a follistatin-derived fusion protein used in laboratory research on locally acting muscle-regulatory pathways.
Understand the science
How the fusion protein was designed to stay local
ACE-083 is an engineered fusion protein containing human FST291, a form of follistatin, joined to the Fc region of human IgG2. An older 2019 study looked at two kinds of binding that mattered for the design.
1 source (2019)
Explore study findings
What the Charcot-Marie-Tooth trial learned from the ankle
ACE-083 is a larger engineered protein that combines a form of follistatin with an antibody Fc region. It was investigated for local muscle growth.
1 source (2022)
What healthy volunteers revealed about a local effect
ACE-083 is a larger follistatin-based fusion protein developed to trap signals in the tissue where it was placed. Its 2018 first-in-human study asked how healthy volunteers tolerated it and whether a selected muscle changed in volume.
2 sources (2018, 2022)
What mouse models could reveal about contraction
ACE-083 is a larger engineered follistatin fusion protein built to capture several growth-regulating proteins locally. A 2019 animal study asked whether muscle enlargement after ACE-083 came with a change in the force that the same muscle could produce.
2 sources (2019, 2022)
Check methods and identity
What newer muscle imaging adds to the ACE-083 story
ACE-083 is a larger engineered fusion protein made from modified follistatin and the Fc region of a human antibody. It was designed to capture signals that restrict muscle growth near the muscle under study.
2 sources (2022, 2026)
Interpret the evidence
Why bigger muscles did not settle the FSHD trial
ACE-083 is an investigational fusion protein based on follistatin. It was engineered to sequester myostatin, activins and other signals around a targeted muscle.
1 source (2022)
